While PARP1-targeted PET imaginghas primarily been developed for oncology applications to date,, its relevance in neurodegenerative diseases, particularly throughparthanatos, makes it an appealing target for advancing neuroimagingof cell death. Here, PARP1 is linked to neurodegenerative disease.